Am J Clin Microbiol Antimicrob | Volume 1, Issue 4 | Mini Review | Open Access
Takuma Hayashi* and Hiroshi Shibuta
Department of Infectious Diseases, University of Tokyo, Japan
*Correspondance to: Takuma Hayashi
Fulltext PDFWe examined mouse immune response to 4 kinds of recombinant vaccinia viruses carrying the human immunodeficiency virus type 1(HIV-1) Group-specific Antigen(gag) gene, including vacgag/ pol, which produces HIV-1-like particles with processed gag proteins; vac-gag, which also produces HIV-1-like particles but with unprocessed gag protein; and vac-gag-pol-fuse and vaces- gag/pol, neither of which produces such virus particles but releases Reverse Transcriptase (RT) and gag protein, respectively, from infected cells. Although infection of mice with recombinant vaccinia viruses induced production of the anti-HIV-1 gag protein 24 (p24) antibodies in all mice, vac-gag/pol and vac-es-pol induced higher production than the other two recombinants. Increase in thymidine [3H] uptake by splenic lymphocytes following HIV-1p24 antigen stimulation was most evident in mice infected with vac-gag/pol. Thus, the highest immune response, both humoral and cellular, was elicited by vac-gag/pol, indicating that among those tested; this recombinant vaccinia virus is the best candidate for a vaccine that induces anti-HIV-1 gag immunity.
Hayashi T, Shibuta H. Immunological Response of Recombinant Vaccinia Virus Including the HIV-1 Gene. Am J Clin Microbiol Antimicrob. 2018; 1(4): 1018.